<SEC-DOCUMENT>0001390478-21-000031.txt : 20210812
<SEC-HEADER>0001390478-21-000031.hdr.sgml : 20210812
<ACCEPTANCE-DATETIME>20210812162601
ACCESSION NUMBER:		0001390478-21-000031
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210812
DATE AS OF CHANGE:		20210812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		211167951

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sls-20210812.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:4413c2c4-6dfe-437d-a650-111c3bf6cb81,g:9a2ca59f-0275-4307-b7cc-1bc9e49c3ee8,d:b4402b9fedd04d6dbcb7e417528c4ebb--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sls-20210812</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl80L2ZyYWc6OGYzYWEwYjVjYjE1NGQ1YWIwZGIwOWY3Yjg1ZWY1YWQvdGFibGU6NDkxNTY5NjhjZWI5NGU2NDkwMGY3ZTNhMmZhNTQxZjkvdGFibGVyYW5nZTo0OTE1Njk2OGNlYjk0ZTY0OTAwZjdlM2EyZmE1NDFmOV8xLTEtMS0xLTA_4d74e0fe-99fb-44a6-bae3-c33724a7ed2a">0001390478</ix:nonNumeric><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl80L2ZyYWc6OGYzYWEwYjVjYjE1NGQ1YWIwZGIwOWY3Yjg1ZWY1YWQvdGFibGU6NDkxNTY5NjhjZWI5NGU2NDkwMGY3ZTNhMmZhNTQxZjkvdGFibGVyYW5nZTo0OTE1Njk2OGNlYjk0ZTY0OTAwZjdlM2EyZmE1NDFmOV8yLTEtMS0xLTA_b6bb059b-2477-463a-9aaa-823863a26322">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sls-20210812.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib4402b9fedd04d6dbcb7e417528c4ebb_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">UNITED STATES <br/>SECURITIES AND EXCHANGE COMMISSION  <br/>WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMjA0_70e6e2d3-09e7-4fc1-a1c7-f452dd2bded5">8-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CURRENT REPORT<br/>PURSUANT TO SECTION 13 OR 15(d) OF THE <br/>SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMzQ_06933bc2-8ab6-4dc0-8184-64d03152446d">August 12, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMTk4_7ea50048-3177-4530-8e54-8d423062289d">SELLAS Life Sciences Group, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8wLTAtMS0xLTA_3e15acfd-4d90-40c3-8c4d-e0e9f69975d9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8wLTItMS0xLTA_8e777fa9-eee1-4375-b7db-263372ae260b">001-33958</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8wLTQtMS0xLTA_4539d2c1-efc5-4069-aae1-1cdbe4037a29">20-8099512</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl81_ff861339-eb97-4094-b32f-1af473b941c8">7 Times Square</ix:nonNumeric>, <ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl85_447558fc-fc10-4346-a7cc-c197530866ab">Suite 2503</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl8xMg_55cbbb03-067a-4436-aef9-5c866770494f">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl8xNg_98f52112-09cf-45d3-8978-061c49f2aad6">NY</ix:nonNumeric> <ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl8xOQ_729d41a5-700e-49ec-b25a-a8499c20c4ae">10036</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV82LTAtMS0xLTAvdGV4dHJlZ2lvbjoxMmY5MGY2M2YwZTM0ZGE3YmQ5NjQ1YzIyN2JkM2NmMl81Ng_e34e930f-d22d-4eb6-aa86-725e38958d15">(646)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV82LTAtMS0xLTAvdGV4dHJlZ2lvbjoxMmY5MGY2M2YwZTM0ZGE3YmQ5NjQ1YzIyN2JkM2NmMl81OQ_8669f819-93ad-4cff-aebd-f48eeb2c40a0">200-5278</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMTk1_33a1ce3a-3349-4829-9f4d-dab652fb86c1">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR&#160;230.425) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMjAw_350722a5-9a36-457f-908a-1ba8b9341002">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR&#160;240.14a-12) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMTk2_0f9f9755-bc9f-439e-88b9-f8480026943c">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR&#160;240.14d-2(b)) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMTk3_f81c2364-fa00-437f-bd48-01f754b9400a">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR&#160;240.13e-4(c)) </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ZDI5NDVmZTY2ZDdiNDFkMzgyY2M3OWM3MzllYjkxYTUvdGFibGVyYW5nZTpkMjk0NWZlNjZkN2I0MWQzODJjYzc5YzczOWViOTFhNV8xLTAtMS0xLTA_e2dfed35-72e3-4776-9d6e-8235b8e0b99b">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ZDI5NDVmZTY2ZDdiNDFkMzgyY2M3OWM3MzllYjkxYTUvdGFibGVyYW5nZTpkMjk0NWZlNjZkN2I0MWQzODJjYzc5YzczOWViOTFhNV8xLTEtMS0xLTA_a9f35474-5d48-450f-9f20-6475cdd01225">SLS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ZDI5NDVmZTY2ZDdiNDFkMzgyY2M3OWM3MzllYjkxYTUvdGFibGVyYW5nZTpkMjk0NWZlNjZkN2I0MWQzODJjYzc5YzczOWViOTFhNV8xLTItMS0xLTA_64761e7e-ceff-40bc-8669-c98855738871">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter). </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMjAz_807c31ea-0bff-4925-8142-e51b32850697">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 12, 2021, SELLAS Life Sciences Group, Inc. (&#8220;SELLAS&#8221;) issued a press release (the &#8220;Press Release&#8221;) announcing its financial results for the quarter ended June 30, 2021 and providing a corporate update.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the SEC made by SELLAS whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slsl-202108128xkexhibit991.htm">Press Release dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slsl-202108128xkexhibit991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slsl-202108128xkexhibit991.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slsl-202108128xkexhibit991.htm">ugust</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slsl-202108128xkexhibit991.htm"> 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slsl-202108128xkexhibit991.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slsl-202108128xkexhibit991.htm">, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELLAS Life Sciences Group, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 12, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>slsl-202108128xkexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9f3abdfdc42e40f1a1eb17b505f78af9_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:112%">SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Cash Position of $29.9 million as of June 30, 2021</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">To Host Virtual Investor Symposium on GPS on August 17, 2021</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NEW YORK, August 12, 2021 - </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS Life Sciences Group, Inc</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(NASDAQ&#58; SLS) (&#34;SELLAS&#34; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We were pleased to report in June updated clinical data for our two earlier stage studies of GPS in combination with PD-1 inhibitors &#8211; the combination of GPS with nivolumab (Opdivo&#174;) in MPM patients and GPS with pembrolizumab (Keytruda&#174;) in advanced ovarian cancer patients. We will continue our analyses as we collect more data over the remainder of the year,&#8221; said Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS. &#8220;We </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">also activated additional clinical sites and continued to enroll patients in the United States and Europe for our Phase 3 REGAL study of GPS in AML patients, and expect to activate additional sites in the European Union (EU) as well as other countries outside of the EU throughout the remainder of 2021.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;Also, we note recently published data in the journal </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Bone Marrow Transplantation </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">regarding the outcomes of AML patients, including those who undergo transplant, which clearly shows that there continues to be a large unmet need in the treatment of AML even among those who successfully receive a transplant but harbor minimal residual disease. In our completed Phase 2 study of AML patients who achieved first remission (CR1), overall survival for patients treated with GPS was 48.5 months from time of enrollment.  The retrospective analysis of the pooled outcomes for AML patients who underwent a transplant in the article published in </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Bone Marrow Transplantation </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">indicates that the median overall survival from the time of transplant is approximately 26 months. Given the results of our studies in AML CR1 patients, we believe that there is strong scientific rationale for consideration of a study in the post-transplantation setting,&#8221; concluded Dr. Stergiou.  </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Pipeline Updates&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Galinpepimut-S (GPS)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In June 2021, a peer-reviewed article was published in the journal </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Bone Marrow Transplantation</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> which included a comprehensive retrospective analysis of survival outcomes in 4,280 AML patients treated in more than 450 blood and marrow transplant centers worldwide between 2007 and 2015. The analysis demonstrates the high unmet medical need to extend survival in AML patients. The published analysis shows that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">even among patients eligible to receive a bone marrow transplant, considered to be the only potential curative therapy in AML, less than half of the patients are alive five years after initial diagnosis. The analysis highlights the importance of the presence of minimal residual disease, or MRD, with patients who harbored MRD at the time of transplant having only 34%-37% probability of surviving five years. In the Company&#8217;s completed Phase 2 study of AML patients who achieved first remission (CR1), overall survival (OS) for patients treated with GPS was 48.5 months from the time of enrollment in the study (67.6 months from initial AML diagnosis). The retrospective analysis of the pooled outcomes for AML patients who underwent a transplant in the article published in </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Bone Marrow Transplantation</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> indicates that the median OS from the time of transplant is approximately 26 months. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In June 2021, the Company reported encouraging updated clinical data from the Phase I open-label investigator-sponsored clinical trial of GPS in combination with the anti-PD-1 therapy nivolumab (Opdivo) in patients with MPM, who harbor relapsed or refractory disease after having received frontline standard of care multimodality therapy. For the four evaluable patients, all of whom had the epithelioid and&#47;or sarcomatoid variant and have received and progressed with, or are refractory to, frontline pemetrexed-based chemotherapy, the average OS was 35.3 weeks with a median OS of 35.4 weeks at a median follow-up of 35.4 weeks. Overall survival for relapsed&#47;refractory patients receiving standard of care (pemetrexed, a chemotherapy) is approximately 28 weeks. Average progression-free survival (PFS) was 8.8 weeks with a median PFS of seven weeks at a median follow-up of 35.4 weeks. The safety profile of the GPS-nivolumab combination was similar to that seen with nivolumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site, which was consistent with previous clinical studies of GPS.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In June, the Company reported updated clinical data and immune response profiles from the basket study of GPS in combination with the anti-PD-1 therapy pembrolizumab (Keytruda) for treating WT1+ advanced ovarian cancer. Of the 11 evaluable patients, 66.7% were refractory to or had failed their second-line therapies and 33.3% had failed third-line or later therapy and all patients were resistant to the standard of care platinum-based therapy. Overall survival for patients receiving standard of care platinum-based therapy is approximately nine to 12 months. The median OS among the patients in this trial is not yet known as all patients remained alive at the time of analysis, which exceeds nine months. In an ad hoc analysis of the clinical outcomes for the cohort of 11 patients, the disease control rate, or DCR, which is the sum of overall response rate and rate of stable disease, was 63.6% with a median follow-up of 15.4 weeks. At the time of follow-up analysis, median PFS was 11.8 weeks. The safety profile of the GPS-pembrolizumab combination was similar to that seen with pembrolizumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site which was consistent with previous clinical studies of GPS.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In May 2021, the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application covering the use of GPS in combination with checkpoint inhibitor therapies for treatment of WT1-expressing cancers.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Corporate and Financial Highlights for the Second Quarter 2021&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In June 2021, the Company received a $1 million milestone payment from 3D Medicines Inc., its licensee for development and commercialization of GPS in the Greater China territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In June 2021, the Company was included in the Russell Microcap&#174; Index</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Membership in the Russell Microcap&#174; Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Financial Results for the Second Quarter 2021&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Licensing revenue&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Licensing revenue was $1.9 million for the second quarter of 2021 and $7.6 million for the first half of 2021 which consists of the recognition of revenue from the Company&#8217;s license agreement with 3D Medicines. The Company did not record any licensing revenue for the first half of 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">R&#38;D Expenses&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Research and development expenses for the second quarter of 2021 were $3.5 million, as compared to $2.3 million for the same period in 2020.  Research and development expenses for the first half of 2021 were $7.7 million as compared to $4.1 million for the same period in 2020. The increase was primarily due to an increase in clinical trial expenses related to the Company&#8217;s Phase 3 REGAL clinical trial of GPS in AML patients and a ramp up of the manufacture of clinical trial materials and registration batches of GPS, a technology transfer to a new contract manufacturer, and clinical drug supply purchase costs in the EU in preparation for opening sites and enrolling patients in EU countries.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">G&#38;A Expenses&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">General and administrative expenses for the second quarter of 2021 were $2.8 million, as compared to $2.0 million for the same period in 2020. General and administrative expenses for the first half of 2021 were $6.4 million, as compared to $4.2 million for the same period in 2020. The increase was primarily due to amortization expense associated with the capitalized contract acquisition costs of the 3D Medicines license agreement as well as an increase in legal fees as compared to the same period in 2020 during which the majority of legal expenses were offset by a reimbursement credit. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Net Loss&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Net loss attributable to common stockholders was $4.6 million for the second quarter of 2021, or a basic and diluted loss per share attributable to common stockholders of $0.30, as compared to a net loss attributable to common stockholders of $4.4 million for the same period in 2020, or a basic and diluted loss per share attributable to common stockholders of $0.66. Net loss attributable to common stockholders was $7.0 million for the first half of 2021, or a basic and diluted loss per share attributable to common stockholders of $0.47, as compared to a net loss attributable to common stockholders of $8.6 million for the same period in 2020, or a basic and diluted loss per share attributable to common stockholders of $1.32.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cash Position&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As of June 30, 2021, cash and cash equivalents totaled approximately $29.9 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Upcoming Investor Symposium</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company will host a virtual investor symposium on its lead asset, GPS, on Tuesday, August 17, 2021, from 1&#58;00 p.m. to 2&#58;00 p.m. ET.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The event will focus on the Company&#8217;s clinical program for GPS, including additional details on its recently released clinical data, as well as the significant unmet need in AML, the indication being studied in the GPS Phase 3 REGAL study. SELLAS management will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies at the Baylor University Medical Center, and member of the REGAL Steering Committee.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To attend the live video webcast, please register or email KCSA Strategic Communications at SELLAS&#64;kcsa.com.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About SELLAS Life Sciences Group, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS&#8217; lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS&#8217; second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For more information on SELLAS, please visit www.sellaslifesciences.com.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Keytruda</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> is a registered trademark of Merck Sharp &#38; Dohme Corp., a subsidiary of Merck &#38; Co., Inc., Kenilworth, N.J., USA, and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products. Opdivo</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> is a registered trademark of Bristol Myers Squibb, and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">This press release contains forward-looking statements. All statements other than statements of historical facts are &#8220;forward-looking statements,&#8221; including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;intend,&#8221; or &#8220;continue&#8221; and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS for ovarian cancer, MPM and AML, and the potential for GPS as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company&#8217;s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption &#8220;Risk Factors&#8221; in SELLAS&#8217; Annual Report on Form 10-K filed on March 23, 2021 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS&#8217; forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other cir</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">cumstances that exist after the date as of which the forward-looking statements were made.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Investor Contacts</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  Valter Pinto &#47; Allison Soss </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">KCSA Strategic Communications </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; SELLAS&#64;kcsa.com </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Phone&#58; 914.907.2675 &#47; 215.272.2707</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media Contacts</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  Caitlin Kasunich &#47; Raquel Cona  </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">KCSA Strategic Communications  </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; SELLAS&#64;kcsa.com </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Phone&#58; 212.896.1241 &#47; 212.896.1276</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of licensing revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,740&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,144&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,358&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,187&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,353&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,453)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,267)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,698)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,331)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income (expense), net&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating expense, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,613)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,425)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,016)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,568)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend arising from warrant modifications</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,613)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,425)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,016)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,646)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share information&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share attributable to common stockholders, basic and diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.32)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,270,288&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,717,900&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,074,887&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,546,440&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.766%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 30, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,917&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,302&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock subscription receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,240&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,318&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,575&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,925&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">896&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,700&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,700&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">623&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,624&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,049&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,657&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,239&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,336&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,896&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,633&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,209&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,088&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.0001&#160;par value&#59; 5,000,000&#160;shares authorized&#59; Series A convertible preferred stock, 17,500 shares designated&#59; no shares issued and outstanding at June 30, 2021 and December 31, 2020</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $0.0001&#160;par value&#59; 350,000,000&#160;shares authorized, 15,873,941 and 14,254,554&#160;shares issued and outstanding at June 30, 2021 and December&#160;31, 2020, respectively.</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,333&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,864&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,920)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117,904)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,415&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,961&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,624&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,049&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sls-20210812.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4413c2c4-6dfe-437d-a650-111c3bf6cb81,g:9a2ca59f-0275-4307-b7cc-1bc9e49c3ee8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sls="http://www.sellaslifesciences.com/20210812" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sellaslifesciences.com/20210812">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20210812_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20210812_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sellaslifesciences.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sls-20210812_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4413c2c4-6dfe-437d-a650-111c3bf6cb81,g:9a2ca59f-0275-4307-b7cc-1bc9e49c3ee8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_fbcf0c17-e32b-4c80-9e90-bf9db33ae6e0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_40d38ad7-b32b-4c9a-8460-a8093edb441e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6bd6610a-7d90-488e-9815-0b25a149194b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9ab27ea7-e42a-41eb-991f-da38d79d9e57_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_26090310-f661-4e60-aa1e-5143f7feb523_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_67982aa6-42e4-429a-a50e-305081c2a241_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a31e126f-41de-4cc3-893f-32143e44d4e7_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_70006c49-5313-4410-88cb-7261229158d3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ac9ca8dc-7f08-4f98-9c10-aa706f8c84d1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_efc83623-a87f-49bb-986c-7d7a49c8b964_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_79d4b38b-ade3-4356-8088-dd3a418ba54f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_14f1f644-5a8a-4298-a34c-1a3d8f425709_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b8b43771-329c-4c22-95d6-ed8f3e3644b1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9f9ab913-3a1b-4b63-81f7-a92a2a8e06f0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b7abee13-a5a6-4c89-9376-6b380d05c2fb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_06593bd4-3e17-4c18-aa41-cf0c027d1615_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7b274c12-1001-425c-9722-e57e4d9878f8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_f82fdd73-3350-4dd7-bc2b-be4b70624fc0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d4468a30-aa8f-4d6b-a749-b1f96d5308b7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8241c36d-e3b2-4838-9c0d-04dc8a22f165_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_64c70b42-a7bd-4849-ae36-b241a6fb37e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_331cec59-76b7-4a92-be3f-33683ee1ce63_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f5df9a24-40f2-40ef-8e22-c082a1e8ae25_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sls-20210812_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4413c2c4-6dfe-437d-a650-111c3bf6cb81,g:9a2ca59f-0275-4307-b7cc-1bc9e49c3ee8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sellaslifesciences.com/role/Cover" xlink:type="simple" xlink:href="sls-20210812.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sellaslifesciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_80266577-ed0e-4a54-9741-e96ef15bc26f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_DocumentType_80266577-ed0e-4a54-9741-e96ef15bc26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_154a2b58-1bf9-4302-a7cb-5f7bf3b65f7a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_DocumentPeriodEndDate_154a2b58-1bf9-4302-a7cb-5f7bf3b65f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fb641c28-7a5e-4a99-b36e-a6ab3a929b1a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityRegistrantName_fb641c28-7a5e-4a99-b36e-a6ab3a929b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_136f0a13-0c3d-4382-886d-6b2dd9bd12ef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityIncorporationStateCountryCode_136f0a13-0c3d-4382-886d-6b2dd9bd12ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_dd90585e-4a34-4843-ae99-e7d2d72f8ac2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityFileNumber_dd90585e-4a34-4843-ae99-e7d2d72f8ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_25fd5d21-f1e1-4daf-8581-a1bce5eb1a2f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityTaxIdentificationNumber_25fd5d21-f1e1-4daf-8581-a1bce5eb1a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_445ade10-0d2e-486b-a1a9-8eb981f4c799" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityAddressAddressLine1_445ade10-0d2e-486b-a1a9-8eb981f4c799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2b82a81b-4e84-4e23-b4be-8072b2ffe620" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityAddressAddressLine2_2b82a81b-4e84-4e23-b4be-8072b2ffe620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_367bfcba-c3d5-49ad-9a8e-e44979fa8a23" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityAddressCityOrTown_367bfcba-c3d5-49ad-9a8e-e44979fa8a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6666fff3-f098-4bdf-abbf-deb81f6fe70f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityAddressStateOrProvince_6666fff3-f098-4bdf-abbf-deb81f6fe70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3b6daf14-bd53-4f7c-94df-7f67c07d0015" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityAddressPostalZipCode_3b6daf14-bd53-4f7c-94df-7f67c07d0015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fa12f54f-a5d2-4ca4-9ab6-638d97a690ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_CityAreaCode_fa12f54f-a5d2-4ca4-9ab6-638d97a690ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2c9f110e-3209-49e6-b019-7682739eef5f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_LocalPhoneNumber_2c9f110e-3209-49e6-b019-7682739eef5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_55627735-01e4-4838-94a1-17691ec19699" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_WrittenCommunications_55627735-01e4-4838-94a1-17691ec19699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_944defbc-df7b-42e7-8ad9-110b87a9dcd7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_SolicitingMaterial_944defbc-df7b-42e7-8ad9-110b87a9dcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c5e0cf0f-e244-4ac1-91f8-85b4a98cbdf8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_PreCommencementTenderOffer_c5e0cf0f-e244-4ac1-91f8-85b4a98cbdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_6dadb89a-4252-4f12-a160-3ad6ce993215" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_6dadb89a-4252-4f12-a160-3ad6ce993215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_16c723f9-6ff1-4399-b20b-15b6a2fa50e3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_Security12bTitle_16c723f9-6ff1-4399-b20b-15b6a2fa50e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_32c26206-bc4b-489b-a88c-93dc5e381dde" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_TradingSymbol_32c26206-bc4b-489b-a88c-93dc5e381dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ffd640e5-fa62-4f9d-95d3-5a6a4dc60ad4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_SecurityExchangeName_ffd640e5-fa62-4f9d-95d3-5a6a4dc60ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a56edfbd-b48c-47ce-9e8b-2be13b2fead4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityEmergingGrowthCompany_a56edfbd-b48c-47ce-9e8b-2be13b2fead4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ebdee301-b179-464f-8190-67afdb4dcbef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_EntityCentralIndexKey_ebdee301-b179-464f-8190-67afdb4dcbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_750e5b07-865d-400d-a801-c13f95dd6fb5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_882c3a82-2f05-4fbe-a642-cf2711fd7685" xlink:to="loc_dei_AmendmentFlag_750e5b07-865d-400d-a801-c13f95dd6fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>sls-20210812_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sls-20210812.xsd" xlink:type="simple"/>
    <context id="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl80L2ZyYWc6OGYzYWEwYjVjYjE1NGQ1YWIwZGIwOWY3Yjg1ZWY1YWQvdGFibGU6NDkxNTY5NjhjZWI5NGU2NDkwMGY3ZTNhMmZhNTQxZjkvdGFibGVyYW5nZTo0OTE1Njk2OGNlYjk0ZTY0OTAwZjdlM2EyZmE1NDFmOV8xLTEtMS0xLTA_4d74e0fe-99fb-44a6-bae3-c33724a7ed2a">0001390478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl80L2ZyYWc6OGYzYWEwYjVjYjE1NGQ1YWIwZGIwOWY3Yjg1ZWY1YWQvdGFibGU6NDkxNTY5NjhjZWI5NGU2NDkwMGY3ZTNhMmZhNTQxZjkvdGFibGVyYW5nZTo0OTE1Njk2OGNlYjk0ZTY0OTAwZjdlM2EyZmE1NDFmOV8yLTEtMS0xLTA_b6bb059b-2477-463a-9aaa-823863a26322">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMjA0_70e6e2d3-09e7-4fc1-a1c7-f452dd2bded5">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMzQ_06933bc2-8ab6-4dc0-8184-64d03152446d">2021-08-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMTk4_7ea50048-3177-4530-8e54-8d423062289d">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8wLTAtMS0xLTA_3e15acfd-4d90-40c3-8c4d-e0e9f69975d9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8wLTItMS0xLTA_8e777fa9-eee1-4375-b7db-263372ae260b">001-33958</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8wLTQtMS0xLTA_4539d2c1-efc5-4069-aae1-1cdbe4037a29">20-8099512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl81_ff861339-eb97-4094-b32f-1af473b941c8">7 Times Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl85_447558fc-fc10-4346-a7cc-c197530866ab">Suite 2503</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl8xMg_55cbbb03-067a-4436-aef9-5c866770494f">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl8xNg_98f52112-09cf-45d3-8978-061c49f2aad6">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV8zLTItMS0xLTAvdGV4dHJlZ2lvbjoyOTRiZjFkNjQ0NTA0MjhkODk5MjIwYTQ4Nzk0MTQ2Nl8xOQ_729d41a5-700e-49ec-b25a-a8499c20c4ae">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV82LTAtMS0xLTAvdGV4dHJlZ2lvbjoxMmY5MGY2M2YwZTM0ZGE3YmQ5NjQ1YzIyN2JkM2NmMl81Ng_e34e930f-d22d-4eb6-aa86-725e38958d15">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ODliNDk2YjgzMTMxNDE2NThiZmI2NWVhOGQ2YmFjODkvdGFibGVyYW5nZTo4OWI0OTZiODMxMzE0MTY1OGJmYjY1ZWE4ZDZiYWM4OV82LTAtMS0xLTAvdGV4dHJlZ2lvbjoxMmY5MGY2M2YwZTM0ZGE3YmQ5NjQ1YzIyN2JkM2NmMl81OQ_8669f819-93ad-4cff-aebd-f48eeb2c40a0">200-5278</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMTk1_33a1ce3a-3349-4829-9f4d-dab652fb86c1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMjAw_350722a5-9a36-457f-908a-1ba8b9341002">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMTk2_0f9f9755-bc9f-439e-88b9-f8480026943c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMTk3_f81c2364-fa00-437f-bd48-01f754b9400a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ZDI5NDVmZTY2ZDdiNDFkMzgyY2M3OWM3MzllYjkxYTUvdGFibGVyYW5nZTpkMjk0NWZlNjZkN2I0MWQzODJjYzc5YzczOWViOTFhNV8xLTAtMS0xLTA_e2dfed35-72e3-4776-9d6e-8235b8e0b99b">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ZDI5NDVmZTY2ZDdiNDFkMzgyY2M3OWM3MzllYjkxYTUvdGFibGVyYW5nZTpkMjk0NWZlNjZkN2I0MWQzODJjYzc5YzczOWViOTFhNV8xLTEtMS0xLTA_a9f35474-5d48-450f-9f20-6475cdd01225">SLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGFibGU6ZDI5NDVmZTY2ZDdiNDFkMzgyY2M3OWM3MzllYjkxYTUvdGFibGVyYW5nZTpkMjk0NWZlNjZkN2I0MWQzODJjYzc5YzczOWViOTFhNV8xLTItMS0xLTA_64761e7e-ceff-40bc-8669-c98855738871">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812"
      id="id3VybDovL2RvY3MudjEvZG9jOmI0NDAyYjlmZWRkMDRkNmRiY2I3ZTQxNzUyOGM0ZWJiL3NlYzpiNDQwMmI5ZmVkZDA0ZDZkYmNiN2U0MTc1MjhjNGViYl8xL2ZyYWc6NmI0OTE5NTlkZjMxNDg1ODgyN2Q3ZGI1MTBmNGMwOTgvdGV4dHJlZ2lvbjo2YjQ5MTk1OWRmMzE0ODU4ODI3ZDdkYjUxMGY0YzA5OF8yMjAz_807c31ea-0bff-4925-8142-e51b32850697">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140069957241144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 12,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8099512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Times Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-5278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>2K?#W";GFE^&4%Z7!G>;7^XC&%O]66Y/#%^N%XC667Y >[0_R&[-R8'LD9
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( $"##%,'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 0(,,4U9+D[7O
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 0(,,4YE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " ! @PQ3&:SRWTP$  #;$
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 0(,,4Y^@&_"Q @  X@P   T              ( !D P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " ! @PQ3EXJ[',     3 @  "P
M        @ %L#P  7W)E;',O+G)E;'-02P$"% ,4    " ! @PQ3JL0B%C,!
M   B @  #P              @ %5$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ 0(,,4R0>FZ*M    ^ $  !H              ( !M1$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 0(,,4V60>9(9 0
MSP,  !,              ( !FA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  Y!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sls-20210812.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="sls-20210812.htm">sls-20210812.htm</File>
    <File>sls-20210812.xsd</File>
    <File>sls-20210812_lab.xml</File>
    <File>sls-20210812_pre.xml</File>
    <File>slsl-202108128xkexhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sls-20210812.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "sls-20210812.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sls-20210812_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sls-20210812_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sls-20210812.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "sls",
   "nsuri": "http://www.sellaslifesciences.com/20210812",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210812.htm",
      "contextRef": "id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sellaslifesciences.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210812.htm",
      "contextRef": "id40c3e50c97d4dec844cb1bdb751bb05_D20210812-20210812",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001390478-21-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-21-000031-xbrl.zip
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M!.1_AXE=UN('+VFF)<N&) A I&V>S0=TO93U**,TTQ&L%W;(&/@*I;KDSTE
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M)=)6Z /H&4?C]LST$'=']0-T_33CR)+N*&A;S5V!_7^'YOV=O#3?GZZ6_>-
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M"F(+>K+//&34HA3"<V)@()"D&(.BA(/]!B=6V1YETD!0T8A$N2-$M2QH!H%
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M-M:Z+*'<BS/<YOM'(8I2&] GNC*,HH<D=1^_#7"W%/853.Y9E$W2LG\Y/P.
M])GJ$\"::9XSQ8!KSF9A4^^=QK"'WF89#'AR'W=\R%H^>$K("^,2&M;%93"+
M =*Y2?Y#>43.V/T(OQV;!CGFL$!D*E 1OS/L8H.@"U1T=LR/(QLN5&7X5SH"
MNN(>XWM0P^BWG>OM!4=RXX(*P7R97<W<2P5_+V&J= BT\7D"W]8K#+_KJD8)
M,L$W @TT[B!!VLK&$3QS0H $],&0@/I1IS3H\![9("*8-_?('T>]0^ #+(LB
M?R$CI$%V% 9R6'9X1[MY<.?$U 0EOJ'UW\,^[J-_XF2934GRO_I1/-@,];*'
ML\C;GSZ?Q<Q94AH2967!AK@IQ-,PK<M=V9ZD3$D>/+O*P)XSB-<Q[]7S!$3.
M?[ DT2I0 :14IM28"6YPUWM;OMY8^(P$[$*AX4GM;Y'[';#C*HJHC)F3U$>/
M>Q1BYAJMQA 3!_E.'=![0QFX8\=6UF6KV@@G6S;0\W==;+[($2*W:T2JQVI8
ML O^A%W K63"XZZ&Y!'DZ0AR#OH"YO'"KM*+J]Y'0S'![R?7=LV5!@K-[BPA
M1[H)*5\Q)A^P4C[59"Z/&M#LA-HZ3K+9Y&4/=T$)@!X((CNY$B:?3;*.%,SL
MR$<^<-!M>3^='&/]'76<_7=C<D]A3&XN?CTJM+>IMK&L?6:Z,[#TFFZ^R&(;
MO=S>R .0)E]W+@2:]KDUN,?,$\'C0K'*2F,/=&*L5>)&Z/GYJ\^Z8Y\YK.O(
M0OL2Y?D9!R@1X7ZM8>[A[>"B226IS[;#AE.< 5L-L+9=-NLC!3[S&C 9D?>N
M@82<L\BY(SU0_B&1V6QR+(8^>OI1:&*Y($[[,0?!C4;CX6K@D3 -W83S!PNX
M]R BW'AQ8?X3?OG2.U0^J^Z6I9./S8XJNIFL;6C?%N[I1\6;!P/N%5*Q,LDA
MF+H(+I.(0!*TC4-=F<29-L1]%G)_3,5(+\Q(OT;PL_#P+,XH)KV_4M[OEX,#
MRJX!%[18B.@!K%CM3(@[-&WR\"M?&MY-.MGB9JA]K#B+\F7A1+;[#/02/;W$
M.%^BB4VSA>_ZF"VY [KX*SA0R'61=%F1@]1>:'U:U>+Y\T-2ID]64F**7P49
MI++<*G,AJB4_%C[6@&(FG8Y%DZ,#A(D#>68;'W"5/$ 'B.NZ:YPZTGO4<.(.
MT!PB_9LZH6SZ5]Q5XG!L()Z^XM/1S$](AND?,:LQ_5L\%*GG3O\*\O/G'!#T
MB38S\,:)S&?.SH)YC)E9<K]R^@)ZBL$8%I!E?2$[O"J[@AI <078'3>6AU("
MBM5)$KJY'QO'@#92R<2L2"+M2JK&?@PI/;A%[1PVBN.FZOOC_%2A=T'7\66)
M>V*_CB'/)D1 97Z*ZMA^[%/K;)D*)&19O3AO[LAG\#_"<LCU:N,+%B'3*,()
MD*^ 4T7_3[4_'#YG9,*/DL.R\S)5Z"(!*WS' XMDAHX']P(TQ$0*#A3^G0I4
M4EPMRG2")7MRZ,BD:E0X/USO\I!;_ =:I+#*[V&U8H M"%D/ SQ,MQFA/(X9
M7D964G >0X.R4/A<G25#F9X/YU14,9\5%MP[MSA\=/GOT^.:U27R(&E?%V/0
M%'&(I2$R>S*)JNBU[#/5AK6:"!RE5;( <*8!.M\_HLYK4^=0B8'*F(Z?,5*M
M7K>I1^7&,5FEN <1+<C:0MB AHY4G-H(9TLO J.3Q)),6'P>H,.HSA_(JNLR
MRM$2?PW/(K_)76SQ6%]/!;^'09#*-D1Y;"G<#';3)U:]]@<9R,UK K=R8,N1
MW2B<Z,I5!EHMJG=RA(,!>G07'UVGW+>,7#/.J* 'HB4.>)<^R*W1%#[)4S E
M7J9@?HR!Y>$U(T %[@*A2PH2:*=EI4@Y7(] @+R!N1"Y"E<?44+SG@;41T3Q
M3YXTEQ1,Z)UTQT#=>+C=72<_U'Y+U,ZR8TAW/LC$TD(0Y'DJ WFDZB0&#-FC
M5 B(C4DC;1!GB-FF.*-O4<<A#/JT3AX]EVM]!&Y0/^)/ODIB1:_)2?U8GL*B
MSY%@WSC6JP9ZYZ6B BVP8_(X467+!Y)S0YWAO-R(Q_>CFU>VT(C\FWI(G"O0
M$X+(W?OHPO(8,S98AB\#;A>D6AZM'I07[A.L?>ASRF?K&R4&_&HH MUAWK6:
M9K?>,>UVIZ6YQK9:IMVQX?]ZIRKDE;J0-U]78>&6EE=1'5&.!Z"0/VB,8C[4
M;'=-_TJ9AV#3A2>$E@#^QY55B0'?!FUE6[:YUVV;EMVT<FV5_=1IK^%:5)KL
MD5,/EWY]3K/;&3R[*FL5WN!R^ML)Z1V=GEP<G?3(Y^O++U<&.;TX6KQ%]DU!
MEZ]G.[J\Z%V>G1X?WIP<D]X-_#D_N;CID<O?R.75R?7AS2D,*#'\.X<^[H'0
M6RI$"G.Y,FGCL##)&CJQZINW=V++U.RAP25:T9> IBZ^R&&UHXU_^:0Z5G/Q
MCB#:1#4H3\K:SSX<N!R/TAOM\T ^6]YTX-/H%@12ZX0Y-1>)%W5Y+*IF78EK
M N D;O9D?=F4EW83=_9:HV%VN^V%E^NFM?#:8]."D]AIM]::]O%K[?IZ=VX/
ML USK][8%& 1LWM+3;LK.5=Q+PA('-+@'Q\:'Z:VZ>_7B24WY&?SY4.[,T/M
M\!L./IC1(S-%3"E+S[?+O_N4ER)%]6:(!]:="WEJZLG$:YQRA3*]R&W&1X]_
M6P(;W\LFXZ%:*V-QVT+[)#N7LO5M",XF7O'WG4M]/RBK/X=\;1U6*D;Z3D9Z
M0C7-!L2.PQ@$Q(^L%\]:F7'_1/B,!]+4EUKKS $/T[SRU!J7)GB=+(F&YR;Z
MDICX\>56?C#]@O"2+-DRNO7ZSS]8[?K!BRT>KZZ(A,?4RU.B-JVB*O;=7O:5
M)6S[H&+@BH$WDX$[1KO2OQ7[;BK[EEO_KNRTZRK6!CCMEZ%\'2,X[:QXV,\R
M8=Y3JUXFQ*OF>.,YGBD>51K5-NU6.=G\",]%P".#GHI1<QS8J^%@KDTIDX:U
MUG4/2N0!;"UQOLO\501Z>0+9E?24ESAO+CW/Y!^6W8@N.N5T+1LZ!P6E9[2&
MT6RU5V2S1TC]4GI@69]QV\ACXSN5*_*4E3P=H].LR%-:\C0-J]E\._*\DT!T
M\?G![R82M8U.MU-YTV4ECV5T]RKRE)8\;:/1VJO(4U;R@!5]2^EYPHIFO>2!
MP--X'J-H-7)RY'.&^(UZ:=V3&SS)&=]H,544^IX0__OJLF42;M2]C?5<Y-(4
MV9\QO-D>PC8-N[VJUJX(NP&$M8"RW57=I8JR&T#9/:/1L$I*V"UN\A[WB^!;
M.+XG9[&0"IO%ASM-H]EJ?'RVGJ5-C=*VAYS@"E3DW!9RMHUV=Z\BY[:04UK]
MDI%SB[M#+T10&R<#>.#@0;$[.BGP$8^M2ZIVT?<T1Y5?+$M^<3/+GT?R'$L\
M_&6 KY52;[+'TQ[Q!24!GE%+^]SCR>C=5$-W[-7=DPUU0C:++E:[HDL9Z=+J
M5G0I(5VL;E7UW+J1[Z2Q>9%7HM[-<"M?6B""F+LR$A+!NVEXWK$:S>6U;=6L
M^8J$::Z0<ZX(\XKN?+LB3#D)L[="XO#U&IO+9_0W962%V+)X?9N9BSK%8^)8
MG.B\]KO).-E5]W!92;-J0TM%FM=K$:Q(4U;2V*W2IIZVJR\\F"@'ZS*PK )7
M_>&Z9E!?.<:HVDS+3=+6"O6YBJ2;0-*&59%TRTAJ-U;HV2Q)&WCY O]-&5DA
MMD+L9HVL$%LA=K-&;O$>I@N65+N7\NTN;:O:O;1%Y&S:K8J<VT+.CE%?HPVU
M(F=)R;EGM-IEVXQ6.5"59[I9([=XO]TQ8SYSB<OON<OPA,"(R\/J!Y'P\STR
MOG#Y@.MWP[^;5M3U#GFN&NPJ E4$J@BT$03:Z:Q>EZJ.JUDJU4-HDD2\GR:T
M[S&2"%BG[XL  !'.W5!XX&#/F-*U_?*E I/J?6/;E/<J67!=L>Y6L^ZSYOC>
MB'77>DMXQ==;S-?/G.RL5'+%NJ^7V&TW2\BZVK'/ ,E@;DK&?.YH;(DY"@MN
MP))<D:(W_I32KZ!\5U!N<31ZQ4 6AS3"HP8&(O)E"G?] ]26K;!5<Y1GCJHJ
M5)7;-FOD%I?;\NQ@"(HYRPA*_;Q$NM @?1IS1[T,DWMIPMSO2=YNCUL_;W&E
M]=SK9F/U+5LE*H94++8!+-9>(3:L6*QBL358K+GZ_J>*Q2H66V$?K-FPJ^KT
M\R+UJ_S"W!H%8.@MF_!!8R+2)$[ O815+.%L+M46,9EY5(B>SLP\DK39K'X*
MJV78G;IA[ZWYOLQGP=+FM5EO.5>TC8[5,;KU55]%7C'%%C,%J(IZIVGLK?ON
MUHHKMI$KVD:KV3::S4U4%54^M$HT;];("K$58C=K9(78"K&;-;)";(78S1I9
M(;9"[&:-K!!;(7:S1E:(K1"[62,E8G=E>Q;\=?G]+Y_D/RI!U\>+.E>WS+7L
M23KYU['#Y" 4,<?VW/V(>33A]^S@@;O)4&<&BW?I_%Y]? OMQP)K=#.W+ 2B
M^.\P;]@/Z2VK]2-&[VITD+!HGWH/=!1//M[G0:T(^(K/+,Q42# Z#%^.L2CA
MVNQV!BLF7*VIA&MG.N%JM0#>WLG9V6&/G)W^=D)Z1Z<G%T<G/?+Y^O++E4%.
M+X[,A91[4]!M^0ZYRXO>Y=GI\>'-R3'Y]?#L$& GO=]/3FYZ)89ZY] 7:9#$
M^.Z[9"A2F,N-#<*^.0QWI*A>R,"5#9+JFTL3^K',*_H2T-3E"7-GH00-(QLZ
M<\&5&7B R:-AS/:S#P>9QN&!G%_>=.#3Z!9$34L[GM,_W4& :U>7QT)HUI4@
M:B.@GZPOF_+25#E!76NWS9:]M_!RW;067GML6JMI=MJMM:9]_%JSN=Z=3P+;
M7FK:^3N=[,9+[72*Q,/3M;*G&Z&5C+QTM:N[5+'KGVG 2*-N$+MN6VOM1WG?
M^#MF#O/[H"<;EL1A?0*'9=N*]UI;K^93R.>NZ['7IM!AKU>TQJM@[7LVK:^#
MR>^98W4@7VF+Q]M0_2B-(GR#+XUCEL3K[[9[:>$KD0"KOHQN:2E*XZ'T2AW\
MP/Y*^3WU@,0KG^!3BK;BY=:\\J[ZM^TJ7FY1=M?H6FMV7)6H<:IBLW*S6:-E
M-.IO^-;+YWQ'7'FU\C6+DX@[$'@KO;R,@LZQL3%'^2V'"VOE[N+R[<FI:%/>
MS2PE5P4]W"9-XK0?.Q$/,25.(HB.00OTO2UXS_*2SHUAK]LX7"+?9ENIL]YA
MN*_G%)2TY+9% &^)VW4$(R+JZ/S&>W&PJK.LRTT?R[#L57==5F[6BDB^BEA(
MN9N]B#N6(9=(AGB8S432\_VX7 UKS;V^E<OU\FF8;JMRM][$>VETRJK";D1"
MO>?05GKU&_!*ZR6%I6FT.JO*RZI(V"#G9WL(VS:Z=ED)N_U:<KW#8=Y&.5Z&
M+*()OO_+8S1F1!*P)@:U%+ZL'^YMH.NP9[UA^:9RZQZG3;==6K=NLSM73H-:
M& F'Q3&)6,QHY*BJFLONF2="'URF]Y+O:1F=JJ164>=]>"T5P)5?^)BX?1;"
M?>">]UZ\/\OH6LW*_ZNH\^X\P&,F]Q06,_O?GR/;).9JVXW*ZRLK;586^Y)6
M^,J>'I\O\D^MM/POE'NAEN02OT]NN14W&T;;7M.DEB;WO_6O0ZRX=P'WMHUZ
MLUM2[GT!;[%,.QS/3@]_/3T[O3D]Z9'#BV/2N[D\^N/WR[/CD^N>;)GJ')"3
M?WTYO?G/]VR!JUX]N(E9@VP?I,=IGWL\X>P[-D-6K]JKLFSOI</VT''4&2DA
M'<W;P/#=,=TF>BOSUE92A\0V[,ZJ)<KR91$J+BLWES6-=FO5K<PES8>46A5'
M*7NTX[G@WKR?^DAGSZKJ(Z6E3M=:-8E=-3YONU,YW=N7J:W1>ZGL6'NKMO25
MSR?;6MJTW]!??A^>S#$;,'!87!*Q>Q:D[V97_)OONZZ\E2=:^=KKOAFQ\E;>
MR3:M[PVQGMK-LE$"TS3LQJK5KI40L$$^SG90U+*-1F--!^AE2;K]VG&3"FH+
M0SB#  YJ6EN^%\>N8U<IJ++29F_E#:=5@^Z*85Q"O[V_',[:GL^&^C<5;5XW
MAU-.F?]*HX@6PJ#UQ'T#S8A5[<(I+6U:E85_N?/U $C,>S@BB+DKG7X1O!<;
MWS16W^!?6?E7[#IIO.$.J?>:D-B(=.TS=<)LS<E+5MVPZV7=F/ &[LWV$';/
MJ.^M>>[C)NXX*8^B.1*^SQ,\B$:UXCF9L^2 TB$[%R)AI/UQH?99;1?'8OJ4
M:*O)DD!N=8 LC_\?"@]P$F>[CO E(,GH76\X>791+[QW54]1P_'[UIZ$Z55I
M?A5EF= 8J6^0'^6K3W5-(*01N:=>RH !N@>D9< E_%]=E2^6!062)D,1P2-=
M-:H'@,#/AZA5) IP_U8X_1RK8[3J=:+G<%D,**))-D<@LBL\CK%S6#8,ITF<
MP <LW="$3+SX4@Y8_"I']>+D+0\JJL/5*_J4*KU;)D6'+H\(EM%RC5;]"3T'
MVJME['4:1K>I%(_5-.Q6TVBUFA-WK*.[U 29 C/P!,&0.?@B>V]D?H<^V\#<
M:'5V:%DI\X8M ^]CF\$A (O9:NH1?%5$C0?$H2%/Z'J'QVV@L;1:>T;C+7.D
ME3/S.'V:8 +;6W*25(D5@>.D?NIA9 1!TH [_-UTINU8=M/HVO69/%3E )2
M-A"_=^O--Z'-]E>O'E&3C;IIM\JJK50!*UZ81ZQ>$0-(:C2,IE76-XF4:??!
MIA'6!I787C4T>BW"/FL%O?PZJ%!$E^F5Y772DI5'A=UY1Y2]]R,0GP,S)97P
M9SCA\QFP\\8^;24@E8"\X"&B;R@@TD;N)GA87)9C+Y0P]$([-F!"'N_.!<S*
M(#;G]^S@@;O)4&.A>)=>3GU\"^T#Y&DR>XNBU2^?^@C%1**_^&]?N"/X,TQ\
M[Y?_!U!+ 0(4 Q0    ( $"##%/D6I1PE14  /*E   0              "
M 0    !S;',M,C R,3 X,3(N:'1M4$L! A0#%     @ 0(,,4S&^SS=O @
MB0<  !               ( !PQ4  '-L<RTR,#(Q,#@Q,BYX<V102P$"% ,4
M    " ! @PQ3I@A5GY@*   180  %               @ %@&   <VQS+3(P
M,C$P.#$R7VQA8BYX;6Q02P$"% ,4    " ! @PQ3WRMIR<\&   ),P  %
M            @ $J(P  <VQS+3(P,C$P.#$R7W!R92YX;6Q02P$"% ,4
M" ! @PQ3/)!-W3XE  #>P0$ '@              @ $K*@  <VQS;"TR,#(Q
K,#@Q,CAX:V5X:&EB:70Y.3$N:'1M4$L%!@     %  4 3 $  *5/      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
